1. Home
  2. QH vs KALA Comparison

QH vs KALA Comparison

Compare QH & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QH

Quhuo Limited American Depository Shares

HOLD

Current Price

$1.15

Market Cap

6.6M

ML Signal

HOLD

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$0.65

Market Cap

6.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QH
KALA
Founded
2012
2009
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6M
6.0M
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
QH
KALA
Price
$1.15
$0.65
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$31.50
AVG Volume (30 Days)
828.8K
22.0M
Earning Date
09-26-2025
11-19-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.33
N/A
Revenue
$357,118,848.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.37
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$0.51
52 Week High
$169.07
$20.60

Technical Indicators

Market Signals
Indicator
QH
KALA
Relative Strength Index (RSI) 40.75 37.46
Support Level $1.23 $0.51
Resistance Level $2.20 $0.67
Average True Range (ATR) 0.25 0.17
MACD 0.12 0.05
Stochastic Oscillator 11.24 10.20

Price Performance

Historical Comparison
QH
KALA

About QH Quhuo Limited American Depository Shares

Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: